Hereditary Hemochromatosis: A Preventable Burden Hidden in Plain Sight

One of the most common inherited genetic disorders in the US is quietly driving cirrhosis, heart failure, and diabetes as well as years of unnecessary specialist care, all largely preventable with a blood test and a timely diagnosis, according to Usha Perepu, MD, a nationally recognized classical hematology expert and director of classical hematology at the Mays Cancer Center at UT Health San Antonio.

Hereditary hemochromatosis affects approximately 1 in 200 to 300 individuals of Northern European ancestry who carry 2 copies of the most common HFE gene mutation (C282Y homozygotes),^1-3 first identified as the cause of the disorder in 1996⁴; roughly 1 in 8 to 10 people carry a single copy of the mutation, according to Perepu, also a professor of medicine in the Division of Hematology and Oncology at the Long School of Medicine at The University of Texas at San Antonio. Despite that prevalence, hereditary hemochromatosis remains substantially underdiagnosed, often silent for decades while iron steadily accumulates in the liver, heart, pancreas, joints, and pituitary gland.⁵

The implications of delayed diagnosis are both clinical and financial: the costs of treating advanced organ damage far outstrip those of early detection and prevention.

“Hereditary hemochromatosis is both detectable and highly treatable,” Perepu told The American Journal of Managed Care^® (AJMC^®). “When diagnosed before significant organ injury develops, most patients can expect a normal life expectancy and excellent quality of life.”

Why Does Hereditary Hemochromatosis Stay Under the Radar?

The reasons behind hereditary hemochromatosis’ ability to escape early detection are systemic. Early symptoms, for those who have them—because some never do^1,4—include fatigue, joint pain, reduced libido, abdominal discomfort, decreased exercise tolerance, and elevated liver enzymes.^1,3,5-8 These are symptoms that overlap extensively with common conditions managed across primary care, rheumatology, endocrinology, gastroenterology, and cardiology; however, iron studies are not part of standard wellness panels, and most professional societies currently recommend targeted rather than universal screening,^9-11 explained Perepu.

Several modifiable and nonmodifiable factors influence whether a genetically susceptible individual progresses to clinical disease, she added. Men tend to develop iron overload earlier because women lose iron through menstruation and pregnancy. Iron accumulation is also gradual but can be accelerated by alcohol consumption, obesity, metabolic dysfunction-associated steatotic liver disease, and viral hepatitis. Regular blood donation can delay accumulation.¹²

What Are Hidden Costs From This Diagnostic Journey?

The path to a hereditary hemochromatosis diagnosis is rarely direct. More often it is a journey with a historical time to correct diagnosis of 5 to 10 years, Perepu explained to AJMC. Patients may cycle through primary care and multiple specialists: rheumatologists for joint pain, gastroenterologists for abnormal liver function tests, endocrinologists for diabetes or low testosterone, and cardiologists for cardiomyopathy.

“During this process, they often undergo extensive laboratory testing, imaging studies, liver evaluations, and cardiac testing before iron studies reveal the underlying diagnosis,” Perepu told AJMC. “Because serum ferritin and transferrin saturation are simple and widely available tests, earlier consideration of hereditary hemochromatosis in patients with compatible symptoms could significantly shorten this diagnostic journey.”

From a health care utilization standpoint, the prediagnosis trajectory represents a meaningful and largely avoidable cost burden. Potential low-cost interventions that could be beneficial early on, such as phlebotomy and periodic iron monitoring, when missed or delayed effectively redistributes disease management to high-cost downstream care. As AJMC has reported, the question of who will cover the costs of genetic screening and whether those costs are offset by downstream savings is central to the policy debate around population-level genetic testing.¹³

Is There An Economic Case for Earlier Intervention?

The treatment for hereditary hemochromatosis is straightforward: therapeutic phlebotomy, in which blood is removed periodically to reduce the body’s iron stores. Perepu explained this process. Treatment unfolds in 2 phases: an iron depletion phase involving weekly or biweekly blood draws until iron stores normalize, followed by a maintenance phase in which blood is removed every few months to prevent reaccumulation.

“When initiated before irreversible organ damage develops, particularly before cirrhosis, advanced diabetes, or significant cardiomyopathy,” Perepu said, “phlebotomy can prevent liver failure [and] cardiac complications, halt progression of iron overload, and eliminate the need for more complex therapies.”

However, the window for maximum benefit is narrow. Joint damage and endocrine dysfunction may not fully reverse once established, underscoring that the clinical and economic value of early intervention depends entirely on the timing of diagnosis.^9,14

“The economic contrast is striking,” Perepu said. Early diagnosis typically involves a blood panel and confirmatory genetic testing when appropriate, followed by phlebotomy, which is a low-cost, repeatable intervention. By contrast, the lifetime costs associated with advanced organ damage are substantially higher. Beyond direct medical expenses, delayed diagnosis also translates into lost productivity, disability, caregiver burden, and diminished quality of life.¹⁵

Hereditary hemochromatosis’ limited presence in health care policy discussions likely stems from several intersecting factors. It develops slowly, making its aggregate population-level burden less visible in utilization data; related complications are frequently managed in isolation without recognition of iron overload as the unifying underlying cause, leading to underestimation of its true burden; and because many genetically susceptible individuals never develop clinical disease, the screening value equation is more complex than it is for conditions with higher penetrance.

Will Universal Screening Ever Get the Green Light?

The question of universal population screening for hereditary hemochromatosis remains unresolved, but the terms of the debate are shifting. Targeted screening of high-risk groups is widely recommended and has demonstrated clear clinical value; these high-risk groups include first-degree relatives of affected individuals and patients with unexplained elevated liver enzymes, abnormal iron studies, early-onset arthritis, or unexplained cardiomyopathy.¹⁶

Universal screening is more contentious. The central challenge is balancing the relatively low cost of testing against the reality of incomplete penetrance. However, Perepu noted that economic models suggest meaningful long-term savings may be achievable.

“If screening successfully identifies individuals before irreversible organ injury occurs, long-term savings from preventing cirrhosis, liver cancer, diabetes, heart disease, and disability could be substantial over 20 to 30 years,” she said. “As genetic testing becomes less expensive and more integrated into routine medical care, the balance may increasingly favor broader screening strategies, particularly in high-prevalence populations.”

The analogy to other genetic conditions with established screening programs is instructive. In the context of genetic testing more broadly, research shows that population-based screening can lead to improvements in population health and cut down on health care costs when specific at-risk groups are identified early and targeted treatments are deployed.¹³ Whether hereditary hemochromatosis reaches the threshold for coverage decisions by payers and managed care organizations will depend on the accumulation of economic evidence—and on whether the condition's diffuse, slow-moving burden becomes legible enough for policy action.

For now, Perepu sees the path forward in clinical awareness rather than technology.

REFERENCES

“The challenge moving forward is not discovering a new treatment. Rather, it is recognizing the disease sooner,” she said. “Greater awareness among clinicians, patients, and policy makers, combined with thoughtful screening strategies for those at increased risk, has the potential to transform hereditary hemochromatosis from a cause of preventable organ damage into a model of successful early detection and precision prevention.”